A roundup of the latest news and updates for patients with Renal Cell Carcinoma from CURE®.
Known as the most common form of kidney cancer in adults, renal cell carcinoma (RCC) has seen an influx of research in recent weeks. Here, CURE® looks back at some of the latest news and updates in the RCC space.
Data presented at the 2020 ASCO Virtual Scientific Meeting demonstrated that MK-6482 appeared to be well tolerated and induced clinical responses among patients with VHL—associated RCC.
Updated study results also presented during the 2020 ASCO Virtual Scientific Meeting showed that Keytruda (pembrolizumab) in combination with Inlyta (axitinib) continued to demonstrate significant improvements in progression-free survival (PFS) and overall survival (OS) compared to Sutent (sunitinib) in patients with previously untreated, advanced RCC.
A recent feature in CURE®’s Immunotherapy issue highlights how advances in a variety of novel treatments, including immunotherapies, are extending life in patients with advanced kidney cancer.
Patients with advanced, previously untreated RCC may soon have a new option in the form of the novel combination of Opdivo (nivolumab) and Cabometyx (cabozantinib), according to study results from the phase 3 CheckMate-9ER trial.
The Food and Drug Administration’s recent approval of a higher recommended dose of Keytruda (pembrolizumab) every six weeks for adults across all cancer types, in which the drug is indicated for, is a welcomed change for patients.
